Overexpression of PD-L1 and PD-L2 is associated with poor prognosis in patients with hepatocellular carcinoma

Cancer Research and Treatment

Volumn 49, Issue 1, 2017, Pages 246-254

  Jung, Hae Il ^a   Jeong, Dongjun ^b   Ji, Sanghee ^b   Ahn, Tae Sung ^a   Bae, Sang Ho ^a   Chin, Susie ^a   Chung, Jun Chul ^a   Kim, Hyung Chul ^a   Lee, Moon Soo ^a   Baek, Moo Jun ^a  

^a Soonchunhyang University   (South Korea)

^b Soonchunhyang University College of Medicine   (South Korea)

Author keywords

Hepatocellular carcinoma; Prognosis; Programmed cell death 1; Programmed cell death 1 ligand

Indexed keywords

BIOLOGICAL MARKER; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 2; PDCD1LG2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL OUTCOME; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL ANALYSIS; TUMOR DIFFERENTIATION; TUMOR RECURRENCE; TUMOR VOLUME; AGED; CANCER GRADING; CANCER STAGING; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADULT; AGED; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN;

EID: 85010369350     PISSN: 15982998     EISSN: 20059256     Source Type: Journal    
DOI: 10.4143/crt.2016.066     Document Type: Article

References (23)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27.
2. Vilarinho S, Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol. 2015;13:219-34.
3. Sangro B, Palmer D, Melero I. Immunotherapy of hepatocellular carcinoma. Hepat Oncol. 2014;1:433-46.
4. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24-33.
5. Ma H, Wey B, Li L. Progress of immunotherapy for hepatocellular carcinoma. Immunogastroenterology. 2013;2: 167-72.
6. Qing Y, Li Q, Ren T, Xia W, Peng Y, Liu GL, et al. Upregulation of PD-L1 and APE1 is associated with tumorigenesis and poor prognosis of gastric cancer. Drug Des Devel Ther. 2015;9:901-9.
7. Pan ZK, Ye F, Wu X, An HX, Wu JX. Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis. J Thorac Dis. 2015;7:462-70.
8. Tentori L, Lacal PM, Graziani G. Challenging resistance mechanisms to therapies for metastatic melanoma. Trends Pharmacol Sci. 2013;34:656-66.
9. Thompson RH, Dong H, Lohse CM, Leibovich BC, Blute ML, Cheville JC, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007; 13:1757-61.
10. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, et al. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 2007;13:2151-7.
11. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007; 104:3360-5.
12. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2:662-73.
13. Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009;15:971-9.
14. Wang BJ, Bao JJ, Wang JZ, Wang Y, Jiang M, Xing MY, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol. 2011;17:3322-9.
15. Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, et al. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6:e23621.
16. He L, Zhang G, He Y, Zhu H, Zhang H, Feng Z. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res. 2005;25:3309-13.
17. Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune suppression. Clin Dev Immunol. 2012;2012:656340.
18. Huber S, Hoffmann R, Muskens F, Voehringer D. Alternatively activated macrophages inhibit T-cell proliferation by Stat6-dependent expression of PD-L2. Blood. 2010;116: 3311-20.
19. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369:134-44.
20. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366: 2443-54.
21. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-64.
22. Tiegs G, Lohse AW. Immune tolerance: what is unique about the l iver. J Autoimmun. 2010;34:1-6.
23. Sangro B, Gomez-Martin C, de la Mata M, Inarrairaegui M, Garralda E, Barrera P, et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013;59:81-8.